Co-Diagnostics Expected to Post $3.75 Per Share Loss, Dwarfing Current Stock Price
CODX sits 27% above its 52-week low of $1.35 on light trading volume (0.2× avg).
Summary
Co-Diagnostics Inc is expected to report a substantial loss of $3.75 per share for the quarter ending March 31, 2026, based on analyst estimates. This projected loss is highly material, as it is more than double the company's current stock price of $1.71, indicating severe financial challenges. This follows the company's 2025 net loss of $46.9 million and a 'going concern' warning, underscoring persistent operational difficulties. Although analysts anticipate a 225.2% increase in quarterly revenue to $163.5 thousand, this modest revenue growth is significantly overshadowed by the magnitude of the expected per-share loss. Traders will be keenly focused on the actual earnings release on May 14, as these dire projections could trigger substantial selling pressure.
At the time of this announcement, CODX was trading at $1.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2M. The 52-week trading range was $1.35 to $46.50. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.